IN2014CN02343A - - Google Patents

Info

Publication number
IN2014CN02343A
IN2014CN02343A IN2343CHN2014A IN2014CN02343A IN 2014CN02343 A IN2014CN02343 A IN 2014CN02343A IN 2343CHN2014 A IN2343CHN2014 A IN 2343CHN2014A IN 2014CN02343 A IN2014CN02343 A IN 2014CN02343A
Authority
IN
India
Prior art keywords
api
capsule
tablet
salt
coating
Prior art date
Application number
Other languages
English (en)
Inventor
Ole Moeller Dall
Original Assignee
Novozymes Biopharma Dk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As
Publication of IN2014CN02343A publication Critical patent/IN2014CN02343A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2343CHN2014 2011-09-02 2012-08-31 IN2014CN02343A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11179819 2011-09-02
PCT/EP2012/066975 WO2013030348A1 (en) 2011-09-02 2012-08-31 Oral formulations containing hyaluronic acid for sustained drug release

Publications (1)

Publication Number Publication Date
IN2014CN02343A true IN2014CN02343A (enExample) 2015-06-19

Family

ID=46755026

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2343CHN2014 IN2014CN02343A (enExample) 2011-09-02 2012-08-31

Country Status (9)

Country Link
US (1) US20140302131A1 (enExample)
EP (1) EP2750665A1 (enExample)
KR (1) KR20140058581A (enExample)
CN (1) CN103781473A (enExample)
AU (1) AU2012300815A1 (enExample)
CA (1) CA2847328A1 (enExample)
IL (1) IL230787A0 (enExample)
IN (1) IN2014CN02343A (enExample)
WO (1) WO2013030348A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114767649A (zh) * 2021-12-22 2022-07-22 北京佗林医药科技有限公司 一种顺式透明质酸六糖的制剂及其制备方法
EP4487834A1 (en) 2023-07-07 2025-01-08 NuPep AS Consensus peptides in hya
EP4487863A1 (en) 2023-07-07 2025-01-08 NuPep AS Consensus peptides in hya for use in treating degenerated joints
EP4739277A1 (en) 2023-07-07 2026-05-13 NuPep AS Consensus peptides in hya

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60251898A (ja) 1984-05-25 1985-12-12 Shiseido Co Ltd 醗酵法によるヒアルロン酸の製造方法
IT1271001B (it) 1994-07-26 1997-05-26 Poli Ind Chimica Spa Procedimento di preparazione di acido ialuronico mediante fermentazione con streptococcus
WO1997028828A1 (en) 1996-02-09 1997-08-14 Amgen Boulder Inc. Composition comprising interleukin-1 inhibitor and controlled release polymer
DK0941349T3 (da) 1996-11-18 2004-02-09 Novozymes Biotech Inc Fremgangsmåde til fremstilling af polypeptider i surfactinmutanter af Bacillusceller
JP4234803B2 (ja) * 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
ATE284954T1 (de) 1997-10-31 2005-01-15 Univ Oklahoma Hyaluronan synthase gen und seine verwendung
CA2326821C (en) 1998-04-02 2010-09-28 The Board Of Regents Of The University Of Oklahoma Nucleic acid encoding hyaluronan synthase and methods of use
US6444447B1 (en) 1998-11-11 2002-09-03 The Board Of Regents Of The University Of Oklahoma Polymer grafting by polysaccharide synthases
JP2005525091A (ja) 2001-12-21 2005-08-25 ノボザイムス バイオポリマー アクティーゼルスカブ 組換え宿主細胞におけるヒアルロナンの生成方法
WO2003061626A1 (en) 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform

Also Published As

Publication number Publication date
KR20140058581A (ko) 2014-05-14
CN103781473A (zh) 2014-05-07
EP2750665A1 (en) 2014-07-09
IL230787A0 (en) 2014-03-31
AU2012300815A1 (en) 2014-02-20
CA2847328A1 (en) 2013-03-07
US20140302131A1 (en) 2014-10-09
WO2013030348A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
MX351584B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
EP4527467A3 (en) Pharmaceutical formulations
MX2013001985A (es) Formulaciones a base de nalbufina y sus usos
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
PH12013502325A1 (en) Drug delivery system
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
PH12014501408A1 (en) Immediate release multi unit pellet system
MY160652A (en) Pharmaceutical composition for oral administration
PH12015500823A1 (en) Modified release formulations for oprozomib
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
MY166972A (en) Transdermal delivery system containing galantamine or salts thereof
ZA202003904B (en) Drug delivery system
EP3010534A4 (en) Pharmaceutical formulations and methods for oral delivery of biologically active ingredient
MX361275B (es) Formulacion de capsula de acido 5-aminosalicilico.
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
IN2012CH05549A (enExample)
WO2013054178A3 (en) Extended release pharmaceutical compositions containing carmabazepine
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
EA201992463A1 (ru) Система доставки лекарственного средства
IN2014CH00984A (enExample)